School of Medicine, One Gustave L. Levy Place, Box. 1074, New York, NY ... global Scientific, Technical, and Medical business to form Wiley-Blackwell. Copyright ...... Myers Squibb/Sanofi. .... 14 Whelton A, fort JG, puma JA, et al. SUCCeSS Vi ...
O r iginal
Pape r
A Comparison of the Blood Pressure Changes of Lumiracoxib With Those of Ibuprofen and Naproxen Michael E. Farkouh, MD;1 Freek W. A. Verheugt, MD;2 Sean Ruland, DO;3 Howard Kirshner, MD;4 Raban Jeger, MD;5 Xavier Gitton, PhD;6 Gerhard Krammer, MSc;6 Kirstin Stricker, PhD;6 Peter Sallstig, MD;6 Bernhard Mellein, PhD;6 Patrice Matchaba, MD;7 James H. Chesebro, MD8
The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal antiinflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P
